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Human adenovirus (HAdV) vectors are promising tools for cancer therapy, but the shortage of efﬁcient
animal models for productive HAdV infections has restricted the evaluation of systemic effects to mainly
immunodeﬁcient mice. Previously, we reported a highly efﬁcient replication of HAdV-2 in a non-
tumorigenic mouse mammary epithelial cell line, NMuMG. Here we show that HAdV-2 gene expression
and progeny formation in NMuMG cells transformed with the SV40 T antigen (NMuMG-T cells) were as
efﬁcient as in the parental NMuMG cells. Injection of HAdV-2 into tumours established by NMuMG-T in
SCID mice caused reduced tumour growth and signs of intratumoural lesions. HAdV-2 replicated within
the NMuMG-T-established tumours, but not in interspersed host-derived tissues within the tumours. The
speciﬁc infection of NMuMG-T-derived tumours was veriﬁed by the lack of viral DNA in kidney, lung or
spleen although low levels of viral DNA was occasionally found in liver.
& 2015 Elsevier Inc. All rights reserved.Introduction
Virotherapy, where a virus is designed to speciﬁcally kill tumour
cells but not normal cells presents a promising trajectory for cancer
therapy. Numerous studies have shown that different human viru-
ses can suppress the growth of tumour cells (Russell et al., 2012)
and among these, human adenoviruses (HAdVs) have emerged as
one of the more attractive candidates since they can be grown to
high titres, are easy to genetically modify and have the ability to
transduce a wide variety of cells, without integrating into the
genome. Clinical studies have also given promising results showing
that oncolytic HAdVs can be both safe and efﬁcient (Hemminki,
2014). Non-replicating HAdV vectors armed with suicide genes have
the drawback of limited access to all cells within a tumour. In
contrast, replicating HAdVs (and preferably conditionally restricted
replicating HAdVs) have the capacity for sequential multiplication,
release and infection of surrounding cells.
HAdVs show strict host speciﬁcity and preclinical research on
clinically useful replicating HAdV vectors has been hampered by the
lack of an experimental animal model system that can efﬁcientlychemistry and Microbiology,
gy, Lund University, Sweden.
rtment of Medical Oncology,
rlands.support HAdV infection and replication. Semi-permissive infections
in rodents have been achieved, but the efﬁciency of wild type HAdV
replication is modest (Hallden, 2003; Jiang et al., 2014; Thomas
et al., 2006), although it can be enhanced by transgenic expression
of surface receptors and viral genes (Kang et al., 2014; Young et al.,
2012). Thus, the antitumour efﬁcacy of oncolytic HAdV is normally
analysed in human xenografts in immunodeﬁcient mice.
We have previously identiﬁed a mouse mammary epithelial cell
line, NMuMG, that supports HAdV-2 replication to the same level
as observed in commonly used and highly permissive human cell
lines, like the lung carcinoma cancer cell line A549 (Wu et al.,
2013). NMuMG cells form well-structured and contact-inhibited
monolayers and are unable to establish tumours in immunodeﬁ-
cient mice (Hynes et al., 1985). In contrast, we show here that
SV40 T antigen-transformed NMuMG cells (NMuMG-T) readily
formed tumours in SCID mice, and that these tumours were highly
permissive to HAdV-2 replication and responded by a signiﬁcantly
reduced tumour growth and signs of cellular destruction.Results and discussion
Establishment of the SV40 T-antigen-transformed cell line NMuMG-LT
The NMuMG cell line is derived from normal mouse mammary
epithelial cells and retains the growth characteristics of non-
transformed primary cells. We recently demonstrated that the
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support replication by a number of HAdV types (Wu et al., 2013).
Since NMuMG cells are essentially non-tumorigenic after trans-
plantation in mice (Hynes et al., 1985) the ability to analyse the
oncolytic properties of HAdV required establishment of a tumori-
genic NMuMG cell line. For this purpose, NMuMG cells were
infected with an SV40 T-expressing retrovirus (Jat et al., 1986) and
after G418 selection, the polyclonal NMuMG-T cells were expan-
ded and the expression of the LT protein was analysed by western
blotting (Fig. 1A). Additionally, the growth kinetics and cell mor-
phology of NMuMG-T were analysed and compared to the parental
NMuMG cell line. SV40 T antigen expression resulted in cells
becoming smaller and growing in less organized foci, thus more
similar to a transformed phenotype (Fig. 1B). Furthermore, the
proliferation rate (Fig. 1C) and saturation density (not shown) of
NMuMG-T cells increased dramatically.
To compare the capacity of NMuMG and NMuMG-T to establish
tumours, 4106 cells were implanted subcutaneously in the right
hind ﬂank of SCID mice. Although implants of the parental
NMuMG cells caused a palpable mass after 3–4 weeks, this mass
disappeared over time. At the termination of the experiment (day
49) no tumour mass could be recovered from mice implanted with
NMuMG cells. In contrast, implanted NMuMG-T cells continued to
grow throughout the experiment and at the end of the experiment
(day 49), tumour masses with an average size of 150 mm3
(approximately 0.2 g) were recovered at the site of injection
(Fig. 1D). These results agree with previous reports describing that
non-tumorigenic NMuMG cells gained the capacity to generate
tumours in immunodeﬁcient mice following introduction of an
activated H-ras gene or the polyoma middle T antigen, respectively
(Hynes et al., 1985; Salomon et al., 1987).Fig. 1. Growth properties of NMuMG and NMuMG-T. (A) Western blotting analysis of S
sparse cell cultures 24 h after seeding. Note the less extensive cell–cell contacts between
NMuMG-T cells. 200,000 cells were seeded in 35 mm plates. At the indicated time po
mean 7 standard deviation from triplicate experiments. (D) Comparison of the abili
implantation. Groups of ﬁve SCID mice each were used and tumour volume and weight
respectively.Efﬁcient virus production in HAdV-2-infected NMuMG-T cells
We have previously shown that HAdV-2 infected NMuMG cells
are as efﬁcient as human A549 cells in producing infectious viral
progeny (Wu et al., 2013). PCR analysis of viral early (E1A) and late
(L3) mRNA expression (Fig. 2A), as well as western blot analysis of
late viral proteins (Fig. 2B) demonstrated that infection of
NMuMG-T cells similarly allowed efﬁcient HAdV-2 replication. To
ensure that NMuMG-T cells also supported HAdV-2 virus pro-
duction, we compared the production of infectious virus particles
following infection of NMuMG and NMuMG-T cells (Fig. 2C). Five
million cells were infected with 10 FFU per cell (Philipson, 1961) of
HAdV-2 and 48 and 60 h post-infection (pi), intracellular virus
particles were isolated and titrated using a limited dilution assay.
The produced number of infectious virus particles per cell (‘burst
size’) was almost identical in NMuMG and NMuMG-T cells
(Fig. 2C). In agreement with our previous results (Wu et al., 2013),
the burst size increased 3–4 fold between 48 and at 60 h pi
(Fig. 2C). Thus, virus production in NMuMG and NMuMG-T cells is
by far the most efﬁcient that has been described in a mouse cell
line so far. Varying, but generally quite modest levels of virus
replication have been demonstrated in different murine cell lines
(Ganly et al., 2000; Hallden, 2003). A recent report describes a
murine lung adenocarcionoma that supports replication of the
oncolytic human adenovirus AdTAV-255 (Zhang et al., 2014). Since
this study did not correlate the replication efﬁciency of AdTAV to
that of wild-type HAdV it is difﬁcult to compare efﬁciencies.
However, from the presented data it appears that the burst size is
signiﬁcantly smaller than what we observe in NMuMG-T cells.
The coxsackie and adenovirus receptor (CAR) is the primary
receptor for most HAdVs, including HAdV-2 (Bergelson et al., 1997)
and the infection efﬁciency of tissue culture cells by CAR-
dependent HAdV vectors correlates with CAR-expression. In theV40 T antigen expression in NMuMG and NMuMG-T cells. (B) The morphology of
NMuMG-T cells compared to NMuMG cells. (C) Proliferation curves of NMuMG and
ints, cells were collected by trypsin/EDTA treatment and counted. Data represent
ty of NMuMG and NMuMG-T cells to establish tumours following subcutaneous
was determined 49 days after the injection. * and ** represent Pr0.05 and Pr0.01
Fig. 2. Efﬁcient replication of HAdV-2 in NMuMG-T cells. (A) RT-PCR analysis of HAdV-2 E1A, L3 and actin mRNA levels in NMuMG-T cells isolated at the indicated time
points after HAdV-2 infection. (B) Expression of late viral protein in NMuMG-T cells at the indicated time points after HAdV-2 infection analysed by western blotting using an
antibody against HAdV-2 virions (Prage et al., 1970). Note that the polyclonal antibody also detects the non-capsid 72 K protein (*). Actin is shown as an internal control. (C)
Production of infectious virus in HAdV-2 infected NMuMG and NMuMG-T cells measured by burst assay. HAdV-2 virus was isolated from infected NMuMG and NMuMG-T
cells at 48 h and 60 h pi, and titrated on either NMuMG or NMuMG-T cells. At day six pi, the cytopathic effect was determined and the burst size of the original infection
calculated. The pairwise combinations denote the cell line used for the ﬁrst infection for 48 h or 60 h followed by the cell line used for the titration assay, respectively. (D)
The expression of CAR in NMuMG and NMuMG-T cells analysed by western blotting. 3T6 cells were used as a negative control. The gradual decrease in CAR expression in
NMuMG or NMuMG-T cells at indicated time points after HAdV-2 infection is shown in the lower part of the ﬁgure.
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the basolateral membrane and therefore not easily accessible for
HAdV upon the ﬁrst encounter with an epithelium (Philipson and
Pettersson, 2004). However, CAR exists in different splice variants,
one of which is present on the apical surface of a polarized epi-
thelium and might mediate the initial binding of HAdV (Excoffon
et al., 2010). Down-regulation of CAR expression during malignant
progression has been demonstrated in different human cancers
(Matsumoto et al., 2005). However, up-regulated CAR expression
has also been described and the discrepant results might possibly
represent alternative regulation of the different splice isoforms
(Dietel et al., 2011). Generally, down-regulated CAR expression
causes resistance to HAdV oncolytic therapy (Li et al., 1999;
Wunder et al., 2012). In agreement with earlier reports (Vincent et
al., 2009) our western blot analysis showed that NMuMG cells
express CAR (Fig. 2D). Notably, expression of SV40 T in NMuMG-T
correlated with a signiﬁcantly reduced expression of CAR (Fig. 2D).
No CAR expression was detected in 3T6 cells serving as a negative
control. Surprisingly, the reduced CAR expression level in
NMuMG-T cells compared to NMuMG did not impair the ability of
HAdV-2 to infect (Fig. 2C), suggesting that CAR was still present in
non-limiting amounts on the cell surface or that infection was
mediated by alternative receptors. Strikingly, a strong repression
of CAR expression was seen upon HAdV-2 infection of both
NMuMG and NMuMG-T cells (Fig. 2D). HAdV infection of human
cells has been shown to reduce CAR expression in persistently
infected lymphocytes, both at the level of reduced cell surface
expression and through transcriptional repression (Zhang et al.,
2010). While the initial elimination of CAR from the cell surface
might depend on its interaction with the adenovirus ﬁber protein
(Zhang et al., 2010), transcriptional silencing of CAR in human
cancer cells appears to involve histone deacetylase activity(Wunder et al., 2012). At the moment it is not clear how the
observed repression of CAR in NMuMG and NMuMG-T cells occurs,
but based on previous reports describing a shift towards tran-
scriptional silencing of host cell genes during the late phase of
HAdV infection it may not be unreasonable to assume that the
promoter activity of CAR is repressed (Zhao et al., 2007).
HAdV-2 reduces growth of NMuMG-T-induced tumours in SCID mice.
To analyse if HAdV-2 could cause cytolytic replication also in
tumours established by NMuMG-T, we performed a pilot experi-
ment where 4106 cells were implanted subcutaneously into the
right hind ﬂank of SCID mice. When the tumours had reached an
average size of 150 mm3, the mice were divided into three groups
and injected intratumorally with 30 ml PBS (two mice), or PBS
containing 109 encapsidated viral genomes of UV-inactivated
HAdV-2 (two mice) or active HAdV-2 (three mice), respectively.
The injections were repeated after seven days and tumour growth
was measured every third day until the animals were sacriﬁced
(Fig. 3A). Both HAdV-2 and UV-inactivated HAdV-2 initially
reduced tumour growth, but at the end of the experiment, a clear
reduction in tumour size was only seen in mice receiving active
HAdV-2 (Fig. 3A and B). The initial reduction in tumour growth
following injection of UV-inactivated HAdV-2 might indicate that
the inactivation step was incomplete. This possibility was sup-
ported by the detection of low amounts of viral DNA in mouse
blood drawn at day 43 (inset Fig. 3A). Additionally, it is also pos-
sible that viral proteins from the UV-inactivated virus exerted a
general inhibitory effect on cell proliferation, but that this gradu-
ally disappeared as the virus was eliminated. At the end of the
experiment no signiﬁcant difference in tumour size between
Fig. 3. HAdV-2 inhibits growth of NMuMG-T-established tumour in SCID mice. (A) Initial analysis of the effect of HAdV-2 on NMuMG-T tumour growth. NMuMG-T cells were
implanted subcutaneously into the ﬂank of SCID mice. After 33 and 40 days (indicated by arrows) HAdV-2, UV-inactivated HAdV-2, or PBS was injected into the established
tumours. Tumour growth was estimated every third day by measuring the size. The data represent mean values of two mice each for the PBS group and the UV-inactivated
virus group and three mice for the HAdV-2 injected group. (B) The end volume of the tumours in Fig. 3A. After 61 days the experiment was terminated and the mice were
sacriﬁced. The volume of the excised tumours was determined. (C) Effect of repeated HAdV-2 injections on NMuMG-T tumour growth. HAdV-2 or PBS was injected into
NMuMG-T tumours at the time points indicated by the arrows and the size of the tumours was estimated every third day. The data represent mean values 7 standard
deviation between all mice within each group (six and ﬁve mice, respectively). (D and E) The end size of the tumours in Fig. 3C. After 57 days the experiment was terminated
and the mice sacriﬁced. The volume (D) and weight (E) of the excised tumours were determined.
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(Fig. 3B).
In a second experiment, 12 SCID mice were implanted sub-
cutaneously with the NMuMG-T cells into the right hind ﬂank.
Following establishment of the tumours, the mice were divided
into two groups that received ﬁve injections (on day 21, 24, 27, 33
and 36) with either HAdV-2 or PBS, respectively. Tumour growth
was followed by caliper measurement every third day. Mice
injected with HAdV-2 exhibited a clear reduction in tumour
growth compared to mice treated with PBS alone (Fig. 3C). At day
57 when the experiment was terminated, the tumours were
excised, measured and weighed. Except for one outlier, tumours
from the HAdV-2-treated mice were signiﬁcantly smaller in size
(Fig. 3D) and weighed less (Fig. 3E) than tumours from PBS-treated
mice. It should be noted that, for unknown reasons one mouse
treated with HAdV-2 died prematurely.
NMuMG-T-induced tumours support replication of HAdV-2
NMuMG cells are derived from mouse mammary gland epi-
thelium and can thus be identiﬁed by immunoﬂuorescent stainingusing epithelial-speciﬁc anti-keratin antibodies. In the absence of
a virus infection the tumours established by NMuMG-T cells dis-
played characteristics of duct/gland structures (Fig. 4A and S1).
These tumours were generally well structured and lacked signs of
necrosis or disintegrated areas, but showed occasional inter-
spersed regions of non-epithelial (negative for keratin) host
stroma cells (arrows in Fig. 4A) and blood vessels (CD31 positive)
(Fig. S1). In contrast, the tumours treated with HAdV-2 were less
structured and also exhibited areas with disruption of the tumour
tissue structures, suggestive of extensive necrosis (Fig. 4B). In
tumours injected with HAdV-2, hexon production overlapped with
keratin-expressing cells indicating that the virus replicated spe-
ciﬁcally in NMuMG-T cells. As expected, interspersed non-
epithelial host cells in the tumours did not stain for hexon
(marked by arrow in Fig. 4B) demonstrating that only NMuMG-T
cells were able to support virus replication. This was further illu-
strated by imaging areas with pronounced inﬁltration of non-
epithelial recipient mouse cells with enhanced signal intensity
(Fig. S2) and at higher magniﬁcation (Fig. S3). Notably, the inten-
sity of the keratin staining was consistently higher in all the virus-
injected tumours than in the PBS-injected tumours, possibly
Fig. 4. Immunostaining of tumour sections. Representative images from immu-
nostaining of tumour tissues recovered at day 57 of the experiment described in
Fig. 3, panels C–E. (A) NMuMG-T-established tumours injected with PBS. (B)
NMuMG-T-established tumours injected with HAdV-2. The sections were immu-
nostained with antibodies against keratin (red) or HAdV hexon protein (green); cell
nuclei were counterstained with Hoechst (blue). The arrows mark non-epithelial
keratin-negative cells derived from the recipient mice.
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(Fig. 4A and B, Fig. S3A and C).
Without expression of a therapeutic transgene it is assumed
that an efﬁcient oncolytic capacity of HAdV relies on continuous
virus infection, replication, cytolysis and release of produced virus.
Immunostaining of excised tumours demonstrated that the HAdV-
2 hexon protein was expressed three weeks after the last injection
of virus (Fig. 4B, S2 and S3), strongly suggesting an efﬁcient and
sustained viral replication. The highly permissive nature of
NMuMG-T cells for HAdV infection agrees with the observation
that the majority of analysed sections of NMuMG-T-established
tumour cells stained positive for hexon expression. In the tumour
sections, the localization of hexon appeared to vary from mainly
cytoplasmic to throughout the cell (Fig. S2). Although the state of
the infected cells in the tumour sections was not addressed
beyond determining their origin as NMuMG-T cells, it is possible
that the differential localization reﬂects that some cells were dead
or dying, whereas others were still alive but at a late stage of
infection.
To verify a sustained replication of HAdV, the excised tumours
were used for extraction of viral DNA and proteins. PCR ampliﬁca-
tion demonstrated that all tumours from mice subjected to intra-
tumoural injection of HAdV-2 contained viral DNA (Fig. 5A).
Quantitative PCR analysis showed an extensive viral DNA replica-
tion in two of the tumours (between 109 and 1010 viral genomes/mg
tissue), moderate in one and modest in two (Fig. 5B). In agreement
with these results, viral structural proteins were easily detectable in
the three tumours with the highest amount of viral DNA, whereaslower amounts of viral proteins were observed in the two samples
with limited viral DNA replication (Fig. 5C). To our knowledge,
sustained HAdV replication following injection of tumours estab-
lished in mice has not been described before. We ﬁnd this result
interesting since repetitive rounds of viral replication is desirable to
obtain extensive HAdV-mediated killing of solid tumours.
PCR analyses failed to demonstrate detectable amounts of viral
DNA in lung, spleen or kidney, in any of the animals injected with
HAdV-2 (Fig. 5D), suggesting that any systemic distribution of
virus from the tumour that may occur did not result in virus
replication at these sites. In the two mice showing the strongest
intratumoral virus replication (Fig. 5A, mouse 1 and 5), the liver
contained detectable amounts of viral DNA (Fig. 5D). However, no
late viral proteins could be detected by western blotting in the
liver (data not shown) suggesting that viral replication did not
occur in livers but that the DNA was more likely taken up by the
liver cells from the circulatory system. This is also consistent with
the general inability of HAdV to replicate in mice and the apparent
lack of viral protein production in the cells surrounding the
tumour tissues (Fig. 4B).
In summary, this study demonstrates that a tumorigenic deri-
vative of NMuMG cells can support replication of HAdV-2 when
grown as tissue culture cells and, more importantly, also after
establishment of tumours in mice. Ongoing replication was
observed three weeks after the ﬁnal injection of HAdV-2. This
correlated with a slow tumour growth and signs of disruption of
tumour structures. NMuMG cells are derived from the mouse
strain Namru (Owens et al., 1974). Despite extensive efforts, we
have not been able to retrieve this strain. We do however believe
that the combination of NMuMG-T cells and Namru (or a another
syngenic mouse strain) would offer an ideal model system for the
expanded investigation of the efﬁcacy of oncolytic HAdVs.Materials and methods
Establishment of NMuMG-T cells
NMuMG cells were infected for 4 h at 37 °C with a recombinant
retrovirus that transduce the SV40 T gene along with a neomycin-
resistance marker gene (Jat et al., 1986) Transduced cells were
obtained after selection with G418 (400 μg/ml). A population of
cells with stable expression of SV40 T protein was veriﬁed by
western blot analysis using an anti-LT antibody (Pallas et al., 1986).
The resulting cell line was termed NMuMG-T.
Adenovirus infection
NMuMG and NMuMG-T cells were mock-infected or infected in
serum-free DMEM with HAdV-2 at a multiplicity of 10 FFU per cell
(Philipson, 1961). After adsorption for one hour at 37 °C in humi-
diﬁed air with 5% CO2, the medium was replaced with DMEM
supplemented with 2% FBS and the infected cells were further
incubated at 37 °C in 5% CO2. At indicated time points cells were
harvested by trypsin/EDTA treatment and the cell pellets were
snap frozen for further RNA, DNA and/or protein extraction.
Tumour models and virus attack
Five weeks old female SCID mice were housed at the BMC
animal facility (Uppsala, Sweden) in individually ventilated cages
(two mice per cage). NMuMG-T cells were suspended in ice-cold
PBS buffer and 4106 cells in a total volume of 100 μl were
implanted subcutaneously in the right hind ﬂank. Mice were
treated with intratumoural injections of 30 μl PBS with or without
1109 encapsidated viral genomes of HAdV-2. UV inactivation of
Fig. 5. HAdV-2 replication in NMuMG-T-established tumours. (A) HAdV-2 DNA in NMuMG-T cell tumours analysed by PCR against the E1A gene. DNA from each of the ﬁve
mice (1–5) described in Fig. 3 panels C–E injected with HAdV-2, as well as one mouse receiving only PBS, was analysed. Actin was used as cellular DNA control. (B) Virus copy
numbers (genomes/mg tissue) in the material used in A was quantiﬁed by qPCR. (C) Expression of structural viral proteins analysed by western blotting of HAdV-2 structural
proteins (Abcam). Samples are as described in A. Actin was used as marker for total protein loading. (D) Presence of HAdV-2 DNA in mouse organs. Viral DNA in different
organs was analysed using PCR against the E1A gene. Actin was used as cellular DNA control. The numbers above each lane represent organs from the mice described in A.
C. Wu et al. / Virology 489 (2016) 44–50 49HAdV-2 was performed essentially as described in (Stein and
Falck-Pedersen, 2012) by irradiating the virus sample at 365 nm
for 20 min in the presence of 1 mg/ml of Psoralen (Sigma, Ger-
many). Tumour growth was monitored by caliper measurement
and the tumour volume was calculated using the ellipsoid volume
formula (lengthwidthdepthπ/6). Blood was collected from
the tail vein of the mice and DNA was isolated using QIAamp DNA
blood Mini kit (Qiagen). The mice were sacriﬁced before the
tumours reached a size larger than 900 mm3. Tumour, liver, spleen
and lung samples from each mouse were isolated separately. A
part of each sample was snap frozen for DNA and protein extrac-
tion, and the remaining tissues were ﬁxed in 4% formalin for
analysis by immunostaining.
DNA and RNA preparation and PCR analysis
To prepare DNA, collected tissue culture cells were resus-
pended in lysis buffer (100 mM NaCl, 10 mM Tris–HCl pH 8.0,
25 mM EDTA pH 8.0, 0.5% SDS and 250 mg/ml proteinase K) and
treated for 2 h at 37 °C. The samples were centrifuged at
12,000 rpm for 30 min, the supernatants were transferred to new
tubes and ethanol-precipitated. The DNA pellets were suspended
in TE-buffer. DNA from mouse tissues was isolated using the same
method except for addition of a ﬁrst step where the frozen sam-
ples were thawed and grinded in lysis buffer.
PCR ampliﬁcation of viral DNA was performed in a thermo-
cycler using 100 ng of DNA in a total volume of 25 ml using primers
for HAdV-2 E1A 50-GTGCCAGCGAGTAGA-30 and 50-GTCAGAAAACC
TGGT-30, and mouse actin 50-GGCTGTATTCCCCTCCATCG-30 and 50-
CCAGTTGGTAACAATGCCATGT-30. The PCR reaction conditions
were: 95 °C 5 min, (95 °C for 20 s, 58 °C for 20 s and 72 °C for
20 s)30 cycles, and 72 °C 10 min. The PCR products were ana-
lysed by electrophoresis in 1.2% agarose gels.
The QPCR was performed using 50 ng DNA and iQTM SYBR
Green Supermix (Bio-Rad) in a Miniopticon Real-Time PCR System(Bio.Rad, CFB-3120) and the E1A primers described above. Cycles
conditions were 95 °C 10 min (95 °C for 15 s, 58 °C for 20 s, and
72 °C for 20 s)40. All samples were analysed in technical
triplicate.
Preparation of mRNA from tissue culture cells, cDNA synthesis
and PCR were performed as described before (Wu et al., 2013).
Protein preparation and western blot analysis
Collected cell pellets were lysed on ice for 30 min in RIPA buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1%
Tween-20 and protease inhibitors (Roche)). Frozen tumour sam-
ples were cut into pieces with a razor blade, grinded in RIPA buffer
and lysed on ice for 30 min. Lysates were centrifuged at
12,000 rpm for 10 min at 4 °C, and the supernatants were col-
lected. 15 μg of protein lysate was mixed with 2 Laemmli sam-
ple buffer (62.5 mM Tris–HCl pH 6.8, 25% glycerol, 0.01% BFB and
2% SDS), boiled for 5 min and separated by SDS-PAGE (10%). Fol-
lowing blotting onto an Immobilon-FL Transfer Membrane (Milli-
pore), the membranes were probed with polyclonal antibodies
directed against puriﬁed HAdV-2 (ab6982, Abcam), (Prage et al.,
1970), β-actin (I-19, sc-1616, Santa Cruz), SV40 T-antigen (Pallas
et al., 1986), CAR (ad153740, Abcam).
End-point dilution assay
Five million NMuMG-T cells were seeded in 10 cm tissue cul-
ture plates and 18 h later infected with HAdV-2 at a multiplicity of
10 FFU/cell (Philipson, 1961). Cell pellets were collected at 48 h
and 60 h pi, respectively. The pellets were suspended in 1 ml
serum-free medium, freeze-thawed three times and cleared from
debris by centrifugation at 10,000g in an Eppendorf centrifuge.
The supernatants were diluted to 10 ml in serum-free medium and
ﬁltered (0.45 μm, Millipore). Each sample was titrated by the
limiting dilution method (tissue culture inhibitory dose at 50%:
C. Wu et al. / Virology 489 (2016) 44–5050TCID50) on sub-conﬂuent monolayers of NMuMG or NMuMG-T
cells in 96-well plates (104 cells/well). Infected plates were incu-
bated at 37 °C in humidiﬁed air containing 5% CO2 for 6 days at
which the wells showing a cytopathic effect were determined
using a DMRIB inverted microscope (Lecia). Each assay was repe-
ated three times and the virus titres expressed as infectious par-
ticles/cell 7SD(Wu et al., 2013)
Immunohistochemistry following HAdV-2 attack on tumours
Cryosections (5 μm) of formalin-ﬁxed tumours were stained
with rabbit polyclonal anti-keratin antibody (C2562, Sigma-
Aldrich), mouse anti-hexon antibody (MAB8052, Millipore) and
anti-CD31 antibody (553370; BD Pharmingen; BD Biosciences).
Secondary goat anti-rabbit antibodies conjugated with Alexa Fluor
594 (Life Technologies, 1:1000) or goat anti-mouse conjugated
with Alexa Fluor 488 (Life Technologies, 1:400) were used. Nuclei
were visualized with Hoechst (H1399, Invitrogen, 1:1000). ProLong
Gold anti-fade reagent (1389854, Life Technologies) was used to
mount stained sections. Pictures were taken with a Nikon Eclipse
90i microscope, using the 20 or 40 objectives and the NIS
Elements 3.2 software with the same exposure time for all
samples.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism
software version 5.01 (GraphPad software, San Diego, CA). Tumour
size in different treatment groups were compared by using two-
way analysis of variance.
Biosafety level and ethics declaration
All experiments using HAdV2 were conducted under biosafety
level 2 and approved by The Swedish Work Environment
Authority. The Uppsala Animal Ethics Committee approved the
animal studies (C215/12).Acknowledgment
This work was supported by grants from the Swedish Cancer
Society. The authors express sincere gratitude to Anna-Karin Ols-
son for support regarding the cell implantation experiments.
The authors declare no conﬂict of interest.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2015.11.031.References
Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S.,
Horwitz, M.S., Crowell, R.L., Finberg, R.W., 1997. Isolation of a common receptor for
Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323.
Dietel, M., Häfner, N., Jansen, L., Dürst, M., Runnebaum, I.B., 2011. Novel splice
variant CAR 4/6 of the coxsackie adenovirus receptor is differentially expressed
in cervical carcinogenesis. J. Mol. Med. 89, 621–630. http://dx.doi.org/10.1007/
s00109-011-0742-6.
Excoffon, K.J.D.A., Gansemer, N.D., Mobily, M.E., Karp, P.H., Parekh, K.R., Zabner, J.,
2010. Isoform-speciﬁc regulation and localization of the coxsackie and adeno-
virus receptor in human airway epithelia. PloS One 5, e9909. http://dx.doi.org/
10.1371/journal.pone.0009909.Ganly, I., Mautner, V., Balmain, A., 2000. Productive replication of human adeno-
viruses in mouse epidermal cells. J. Virol. 74, 2895–2899.
Hallden, G., 2003. Novel immunocompetent murine tumor models for the assess-
ment of replication-competent oncolytic adenovirus efﬁcacy. Mol. Ther. 8,
412–424. http://dx.doi.org/10.1016/S1525-0016(03)00199-0.
Hemminki, A., 2014. Oncolytic immunotherapy: where are we clinically? Scienti-
ﬁca, 1–7. http://dx.doi.org/10.1155/2014/862925.
Hynes, N.E., Jaggi, R., Kozma, S.C., Ball, R., Muellener, D., Wetherall, N.T., Davis, B.W.,
Groner, B., 1985. New acceptor cell for transfected genomic DNA: oncogene
transfer into a mouse mammary epithelial cell line. Mol. Cell. Biol. 5, 268–272.
Jat, P.S., Cepko, C.L., Mulligan, R.C., Sharp, P.A., 1986. Recombinant retroviruses
encoding simian virus 40 large T antigen and polyomavirus large and middle T
antigens. Mol. Cell. Biol. 6, 1204–1217.
Jiang, H., Clise-Dwyer, K., Ruisaard, K.E., Fan, X., Tian, W., Gumin, J., Lamfers, M.L.,
Kleijn, A., Lang, F.F., Yung, W.-K.A., Vence, L.M., Gomez-Manzano, C., Fueyo, J.,
2014. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an
immunocompetent mouse model. PloS One 9, e97407. http://dx.doi.org/
10.1371/journal.pone.0097407.
Kang, S., Kim, J.-H., Kim, S.Y., Kang, D., Je, S., Song, J.J., 2014. Establishment of a
mouse melanoma model system for the efﬁcient infection and replication of
human adenovirus type 5-based oncolytic virus. Biochem. Biophys. Res. Com-
mun., 1–6. http://dx.doi.org/10.1016/j.bbrc.2014.09.107.
Li, Y., Pong, R.C., Bergelson, J.M., Hall, M.C., Sagalowsky, A.I., Tseng, C.P., Wang, Z.,
Hsieh, J.T., 1999. Loss of adenoviral receptor expression in human bladder
cancer cells: a potential impact on the efﬁcacy of gene therapy. Cancer Res. 59,
325–330.
Matsumoto, K., Shariat, S.F., Ayala, G.E., Rauen, K.A., Lerner, S.P., 2005. Loss of
coxsackie and adenovirus receptor expression is associated with features of
aggressive bladder cancer. Urology 66, 441–446. http://dx.doi.org/10.1016/j.
urology.2005.02.033.
Owens, R.B., Smith, H.S., Hackett, A.J., 1974. Epithelial cell cultures from normal
glandular tissue of mice. J. Natl. Cancer Inst. 53, 261–269.
Pallas, D.C., Schley, C., Mahoney, M., Harlow, E., Schaffhausen, B.S., Roberts, T.M.,
1986. Polyomavirus small t antigen: overproduction in bacteria, puriﬁcation,
and utilization for monoclonal and polyclonal antibody production. J. Virol. 60,
1075–1084.
Philipson, L., 1961. Adenovirus assay by the ﬂuorescent cell-counting procedure.
Virology 15, 263–268.
Philipson, L., Pettersson, R.F., 2004. The coxsackie-adenovirus receptor – a new
receptor in the immunoglobulin family involved in cell adhesion. Curr. Top.
Microbiol. Immunol. 273, 87–111.
Prage, L., Pettersson, U., Hoglund, S., Lonberg-Holm, K., Philipson, L., 1970. Struc-
tural proteins of adenoviruses. IV. Sequential degradation of the adenovirus
type 2 virion. Virology 42, 341–358.
Russell, S.J., Peng, K.-W., Bell, J.C., 2012. Oncolytic virotherapy. Nat. Biotechnol. 30,
658–670. http://dx.doi.org/10.1038/nbt.2287.
Salomon, D.S., Perroteau, I., Kidwell, W.R., Tam, J., Derynck, R., 1987. Loss of growth
responsiveness to epidermal growth factor and enhanced production of alpha-
transforming growth factors in ras-transformed mouse mammary epithelial
cells. J. Cell. Physiol. 130, 397–409. http://dx.doi.org/10.1002/jcp.1041300313.
Stein, S.C., Falck-Pedersen, E., 2012. Sensing adenovirus infection: activation of
interferon regulatory factor 3 in RAW 264.7 cells. J. Virol. 86, 4527–4537. http:
//dx.doi.org/10.1128/JVI.07071-11.
Thomas, M.A., Spencer, J.F., La Regina, M.C., Dhar, D., Tollefson, A.E., Toth, K., Wold,
W.S.M., 2006. Syrian hamster as a permissive immunocompetent animal model
for the study of oncolytic adenovirus vectors. Cancer Res. 66, 1270–1276. http:
//dx.doi.org/10.1158/0008-5472.CAN-05-3497.
Vincent, T., Neve, E.P.A., Johnson, J.R., Kukalev, A., Rojo, F., Albanell, J., Pietras, K.,
Virtanen, I., Philipson, L., Leopold, P.L., Crystal, R.G., de Herreros, A.G., Mous-
takas, A., Pettersson, R.F., Fuxe, J., 2009. A SNAIL1–SMAD3/4 transcriptional
repressor complex promotes TGF-β mediated epithelial–mesenchymal transi-
tion. Nat. Cell Biol. 11, 943–950. http://dx.doi.org/10.1038/ncb1905.
Wu, C., Öberg, D., Rashid, A., Gupta, R., Mignardi, M., Johansson, S., Akusjärvi, G.,
2013. A mouse mammary epithelial cell line permissive for highly efﬁcient
human adenovirus growth. Virology 435, 363–371. http://dx.doi.org/10.1016/j.
virol.2012.10.034.
Wunder, T., Schmid, K., Wicklein, D., Groitl, P., Dobner, T., Lange, T., Anders, M.,
Schumacher, U., 2012. Expression of the coxsackie adenovirus receptor in
neuroendocrine lung cancers and its implications for oncolytic adenoviral
infection. Cancer Gene Ther. 20, 25–32. http://dx.doi.org/10.1038/cgt.2012.80.
Young, A.-M., Archibald, K.M., Tookman, L.A., Pool, A., Dudek, K., Jones, C., Williams, S.L.,
Pirlo, K.J., Willis, A.E., Lockley, M., McNeish, I.A., 2012. Failure of translation of
human adenovirus mRNA in murine cancer cells can be partially overcome by L4-
100K expression in vitro and in vivo. Mol. Ther. 20, 1676–1688. http://dx.doi.org/
10.1038/mt.2012.116.
Zhang, L., Hedjran, F., Larson, C., Perez, G.L., Reid, T., 2014. A novel immuno-
competent murine model for replicating oncolytic adenoviral therapy. Cancer
Gene Ther. 22, 17–22. http://dx.doi.org/10.1038/cgt.2014.64.
Zhang, Y., Huang, W., Ornelles, D.A., Gooding, L.R., 2010. Modeling adenovirus
latency in human lymphocyte cell lines. J. Virol. 84, 8799–8810. http://dx.doi.
org/10.1128/JVI.00562-10.
Zhao, H., Granberg, F., Pettersson, U., 2007. How adenovirus strives to control cel-
lular gene expression. Virology 363, 357–375. http://dx.doi.org/10.1016/j.
virol.2007.02.013.
